<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T18:59:58Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/222839" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/222839</identifier><datestamp>2026-03-05T19:09:16Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478858</setSpec><setSpec>col_2072_478916</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:Item id="hdl_2445_222839">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:2445/222839</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Analytical Interference of Exemestane With Androstenedione Immunoassays</dc:title>
               <dc:creator>Giralt, Marina</dc:creator>
               <dc:creator>Ferrer, Roser</dc:creator>
               <dc:creator>Díaz Troyano, Noelia</dc:creator>
               <dc:creator>Vega, Belén</dc:creator>
               <dc:creator>Luque Ramírez, Manuel</dc:creator>
               <dc:creator>Martínez, Sílvia</dc:creator>
               <dc:creator>Fernández, Bárbara</dc:creator>
               <dc:creator>Martínez Serrano, Irene</dc:creator>
               <dc:creator>Fabregat, Aleix</dc:creator>
               <dc:creator>Urgell, Eulàlia</dc:creator>
               <dc:creator>Cardona, Ignasi</dc:creator>
               <dc:creator>Casals, Gregori</dc:creator>
               <dc:creator>Escobar Morreale, Héctor F.</dc:creator>
               <dc:subject>Farmacovigilància</dc:subject>
               <dc:subject>Radioimmunoassaig</dc:subject>
               <dc:subject>Drug monitoring</dc:subject>
               <dc:subject>Radioimmunoassay</dc:subject>
               <dc:description>Background: Exemestane, an aromatase inhibitor commonly used for breast cancer treat- ment, shares structural similarities with sex steroids analyzed in clinical laboratories. We aimed to investigate the influence of exemestane cross-reactivity in the measurement of sex steroids across various immunoassays. Methods: We conducted a multicenter study involving measurements of androstenedione, testosterone, estradiol, progesterone , 17-hydroxyprogesterone in serum samples from women undergoing exemestane therapy (N =15; 25 mg/day). Measurements were per- formed using liquid chromatography-mass spectrometry (LC-MS) , various commercially available chemiluminescence immunoassays, ELISA, and radioimmunoassay. In-vitro cross-reactivity was assessed by adding exemestane and 17-hydroexemestane to serum samples. Results: Patients undergoing exemestane therapy had markedly falsely elevated andro- stenedione results in all immunoassays evaluated (N = 4), which correlated with serum ex- emestane levels. In-vitro experiments confirmed this interference to be caused by cross-re- activity with exemestane. Additionally, one immunoassay yielded falsely elevated estradiol results in 20% of patients. However, in-vitro experiments did not confirm this to be caused by cross-reactivity with exemestane or 17-hydroexemestane. Conclusions: Exemestane cross-reacts with androstenedione immunoassays, causing falsely elevated results in treated patients. This analytical interference may raise unneces- sary concerns, leading to expensive diagnostic workups.</dc:description>
               <dc:date>2025-08-29T11:28:50Z</dc:date>
               <dc:date>2025-08-29T11:28:50Z</dc:date>
               <dc:date>2025-03-21</dc:date>
               <dc:date>2025-08-26T10:01:23Z</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:relation>Reproducció del document publicat a: https://doi.org/10.3343/alm.2024.0362</dc:relation>
               <dc:relation>Annals of Laboratory Medicine, 2025, vol. 45, num. 4, p. 410-419</dc:relation>
               <dc:relation>https://doi.org/10.3343/alm.2024.0362</dc:relation>
               <dc:rights>cc by-nc-nd (c) Giralt, Marina et al, 2025</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Annals of Laboratory Medicine</dc:publisher>
               <dc:source>Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>